ArticleAnalytical cellular pathology (Amsterdam)2026
Deciphering HPV-Associated Immune Evasion in Cervical Cancer Through Multi-Omics Profiling and Computational Screening.
Article in Analytical cellular pathology (Amsterdam), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deciphering HPV-Associated Immune Evasion in Cervical Cancer Through Multi-Omics Profiling and Computational Screening.Analytical cellular pathology (Amsterdam) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHuman papillomavirus (HPV) infection is a major contributor to cervical cancer (CC), yet the molecular mechanisms driving HPV-associated immune evasion remain largely undefined.
methodsBulk RNA-seq (The Cancer Genome Atlas [TCGA]-CESC) and single-cell RNA-seq datasets (GSE171894, GSE197461) were analyzed to elucidate transcriptional and immune landscape differences between HPV-positive and HPV-negative cervical tumors. Differentially expressed genes (DEGs) were identified using DESeq2. Functional enrichment analyses were conducted through gene set enrichment analysis (GSEA), gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) methodologies. Immune evasion feature genes were selected employing LASSO, Random Forest, and SVM-RFE techniques. Regulatory networks for transcription factors and miRNAs were constructed. Immune infiltration was evaluated using CIBERSORT and ssGSEA. Validation of key signature genes was performed in CC cell lines (HeLa, SiHa, C33A, and W12) via real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot. The functional roles of IFNGR1 were examined through siRNA-mediated knockdown, complemented by CCK-8, colony formation, Transwell migration/invasion, and flow cytometry apoptosis assays.
resultsA total of 6266 DEGs effectively differentiated HPV-positive from HPV-negative tumors. HPV-positive tumors exhibited enrichment in viral infection and immune response pathways, while HPV-negative tumors demonstrated activation of oncogenic signaling. Machine learning algorithms identified IFNGR1, TRADD, and PSMB9 as immune evasion feature genes associated with HPV. Regulatory network analysis emphasized IRF1/IRF2 and several miRNAs as critical modulators. Immune infiltration analysis indicated increased infiltration of Dendritic and Plasma cells in HPV-positive tumors, correlating with TRADD expression. Kaplan-Meier analysis further showed a trend toward worse overall survival among HPV-positive patients with high IFNGR1 expression (hazard ratio [HR] = 1.78, 95% confidence interval [CI]: 0.86-3.68; log-rank p = 0.113). Notably, IFNGR1 was significantly upregulated in HPV-positive CC cell lines at both mRNA and protein levels. IFNGR1 knockdown markedly inhibited proliferation, colony formation, migration, and invasion, while enhancing apoptosis in HeLa and SiHa cells, thereby confirming its essential role in the progression of HPV-associated CC.
conclusionThis study identified IFNGR1 as a key immune evasion-related gene in HPV-positive CC, elucidating its regulatory network and functional contributions, while positioning it as a potential therapeutic target for HPV-associated tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.